Key result
Prostaglandin E1 infusion increased myocardial contractility in conscious dogs, with systolic segmental shortening reaching a 33% increase (p<0.001) when basal end-diastolic length was restored.
Why the study?
Does prostaglandin E1 increase myocardial contractility in conscious dogs?
Population
20 unanesthetized dogs with implanted ultrasonic dimension gauges in the subendocardium and a micromanometer…
Comparison
Prostaglandin E1 infused into the left atrium at… vs Placebo infusion
Design
Preclinical
Authors
Loading...
PGE1 shows inotropic effects in conscious dogs; leaves open translation to human heart failure therapy.
Does prostaglandin E1 increase myocardial contractility in conscious dogs?
Effect estimate: 33% increase
p-value: p=<0.001
Prostaglandin E1 demonstrates positive inotropic effects in addition to its potent vasodilating properties in conscious dogs.
Roux et al. (1984) studied this question. Prostaglandin E1 (PGE1) vs. Placebo was evaluated on Myocardial contractility (delta L: systolic segmental shortening) (33% increase, p=<0.001). Prostaglandin E1 infusion increased myocardial contractility in conscious dogs, with systolic segmental shortening reaching a 33% increase (p<0.001) when basal end-diastolic length was restored.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: